MedInCell Stock Drops 2% to €28.14 Despite Raised Target of €52 by Oddo
The Montpellier-based biotech's stock fell 2.02% to €28.14 at midday in a sluggish Paris market. The SBF 120 is down 1.36% in session and the CAC 40 has declined by 1.42%. However, the stock still maintains a gain of nearly 82% over the year and 6.8% over the week.
Oddo BHF Raises Target to €52, Evercore ISI Lowers Its to €36
Two analyst notes dated May 14 are stirring interest in MedInCell. Oddo BHF has raised its price target from €50 to €52, maintaining an outperform rating. Evercore ISI also maintains an outperform rating but has lowered its target from €43 to €36. Based on the midday price of €28.14, Oddo BHF's target implies a theoretical potential of about 85%, while Evercore ISI's target suggests a potential of about 28%. Both firms remain buyers despite diverging valuation trajectories. The market can view the detailed recommendations to understand these opinions within the consensus.
Stock Enters Overbought Territory at 94% of Upper Bollinger Band
The session's decline comes after several days of acceleration. The price at €28.14 is positioned at the high end of the Bollinger Bands, at 94% of its upper limit set at €28.55. The RSI at 72 confirms an overbought configuration. The stock remains well above its 50-day moving average (€23.37, a 20.4% difference) and its 200-day average (€24.64, a 14.2% difference), reflecting the bullish trajectory of recent weeks. The technical resistance identified at €28.72 now limits the movement. For reference, the company's R&D day on May 11 supported the stock. The next calendar event is the 2026 general meeting, scheduled for September 10.
